Beam Therapeutics Inc.
Cambridge, Massachusetts, United States · Biotechnology, Healthcare, Health Care
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting
You have opened 5 full company profiles today. Create an account to keep reading them. Create an account
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (BEAM)
- Website
- beamtx.com
- Company page
Recent activity at Beam Therapeutics Inc.
- : Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
- : SEC 8-K (1.02): On March 2, 2026, Beam Therapeutics Inc. and Bio Palette Co., Ltd. mutually terminated their License Agreement originally dated March 27, 2019, due to the planned dissolution of Bio Palette. This termination was formalized through a Termination Agreement executed on the same date. Prior to this termination, Bio Palette and Kobe University had also terminated their License Agreement, which activated a standby license for Beam Therapeutics under a Standby License Agreement effective February 9, 2026, thus ensuring that Beam retained rights to patents associated with base editing for certain treatments. The License Agreement was concluded in its entirety, releasing both parties from future claims and obligations regarding payments under the agreement. This development reflects significant strategic changes within the companies involved, particularly as it relates to their operations in the biotechnology field.
- : SEC 8-K (1.01): On February 24, 2026, Beam Therapeutics Inc. entered into a Financing Agreement, establishing a senior secured term loan facility of up to $500 million. The Credit Facility includes an initial draw of $100 million on the Closing Date and allows for additional draws totaling $400 million upon achieving certain FDA approvals and revenue targets for the drug risto-cel. The facility matures on February 24, 2033, and bears an interest rate linked to the 3-month Secured Overnight Financing Rate plus a margin. Additionally, the agreement includes various covenants, including maintaining certain liquidity levels based on market capitalization, with all obligations secured by the Company's assets. The event date of February 24, 2026, marks a significant financial agreement aimed at bolstering the Company's operational funding and strategic initiatives.
Employee benefit plans
Beam Therapeutics Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
About Beam Therapeutics Inc.: questions and answers
What does Beam Therapeutics Inc. do?
Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc. is headquartered in Cambridge, Massachusetts, United States.
What is the latest news on Beam Therapeutics Inc.?
On Sep 01, 2026, Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Is Beam Therapeutics Inc. a public company?
Yes. Beam Therapeutics Inc. is publicly traded under the ticker BEAM.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy